drugset / Trial / NCT06171321
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In recent years, circulating tumor DNA (ctDNA)had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. The presence of ctDNA after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
Timeline
- Start
- 2023-12
- Primary completion
- 2025-11-15
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1 | Small molecule | — | Intravenous |